​

Coya Therapeutics (COYA) Stock Forecast, Price Target & Predictions

OverviewRevenueFinancialsChart

COYA Stock Forecast

Coya Therapeutics stock forecast is as follows: an average price target of $18.00 (represents a 243.51% upside from COYA’s last price of $5.24) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.

COYA Price Target

The average price target for Coya Therapeutics (COYA) is $18.00 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $18.00 to $18.00. This represents a potential 243.51% upside from COYA's last price of $5.24.

COYA Analyst Ratings

Buy

According to 3 Wall Street analysts, Coya Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for COYA stock is 0 'Strong Buy' (0.00%), 3 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Coya Therapeutics Price Target by Analyst

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Sep 16, 2024Raghuram SelvarajuH.C. Wainwright$18.00$6.12194.12%243.51%

The latest Coya Therapeutics stock forecast, released on Sep 16, 2024 by Raghuram Selvaraju from H.C. Wainwright, set a price target of $18.00, which represents a 194.12% increase from the stock price at the time of the forecast ($6.12), and a 243.51% increase from COYA last price ($5.24).

Coya Therapeutics Price Target by Period

1M3M12M
# Anlaysts--1
Avg Price Target--$18.00
Last Closing Price$5.24$5.24$5.24
Upside/Downside-100.00%-100.00%243.51%

In the current month, the average price target of Coya Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Coya Therapeutics's last price of $5.24. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Sep 16, 2024H.C. WainwrightBuyInitialise
Jun 12, 2024Rodman & RenshawBuyInitialise
Jun 08, 2023Chardan CapitalBuyBuyHold

Coya Therapeutics's last stock rating was published by H.C. Wainwright on Sep 16, 2024. The company Initialise its COYA rating from "null" to "Buy".

Coya Therapeutics Financial Forecast

Coya Therapeutics Revenue Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Dec 23
Revenue-------$6.00M
Avg Forecast$450.00K$3.17M$1.63M$133.33K$100.00K$1.88M$2.75M$7.50M
High Forecast$450.00K$3.17M$1.63M$133.33K$100.00K$1.88M$2.75M$7.50M
Low Forecast$450.00K$3.17M$1.63M$133.33K$100.00K$1.88M$2.75M$7.50M
# Analysts11123111
Surprise %-------0.80%

Coya Therapeutics's average Quarter revenue forecast for Jun 24 based on 1 analysts is $2.75M, with a low forecast of $2.75M, and a high forecast of $2.75M. COYA's average Quarter revenue forecast represents a -54.18% decrease compared to the company's last Quarter revenue of $6.00M (Dec 23).

Coya Therapeutics EBITDA Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Dec 23
# Analysts11123111
EBITDA-------$2.02M
Avg Forecast$225.00K$1.58M$816.67K$66.67K$50.00K$937.50K$1.38M$3.75M
High Forecast$225.00K$1.58M$816.67K$66.67K$50.00K$937.50K$1.38M$3.75M
Low Forecast$225.00K$1.58M$816.67K$66.67K$50.00K$937.50K$1.38M$3.75M
Surprise %-------0.54%

1 analysts predict COYA's average Quarter EBITDA for Jun 24 to be $1.38M, with a high of $1.38M and a low of $1.38M. This is -31.77% lower than Coya Therapeutics's previous annual EBITDA (Dec 23) of $2.02M.

Coya Therapeutics Net Income Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Dec 23
# Analysts11123111
Net Income-------$1.27M
Avg Forecast$-6.90M$-2.28M$-4.87M$-5.48M$-4.19M$-5.51M$-2.59M$3.92M
High Forecast$-6.90M$-2.28M$-4.87M$-5.48M$-4.19M$-5.51M$-2.59M$3.92M
Low Forecast$-6.90M$-2.28M$-4.87M$-5.48M$-4.19M$-5.51M$-2.59M$3.92M
Surprise %-------0.32%

Coya Therapeutics's average Quarter net income forecast for Jun 24 is $-2.59M, with a range of $-2.59M to $-2.59M. COYA's average Quarter net income forecast represents a -304.40% decrease compared to the company's last Quarter net income of $1.27M (Dec 23).

Coya Therapeutics SG&A Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Dec 23
# Analysts11123111
SG&A-------$2.38M
Avg Forecast$484.32K$3.41M$1.76M$143.50K$107.63K$2.02M$2.96M$8.07M
High Forecast$484.32K$3.41M$1.76M$143.50K$107.63K$2.02M$2.96M$8.07M
Low Forecast$484.32K$3.41M$1.76M$143.50K$107.63K$2.02M$2.96M$8.07M
Surprise %-------0.29%

Coya Therapeutics's average Quarter SG&A projection for Jun 24 is $2.96M, based on 1 Wall Street analysts, with a range of $2.96M to $2.96M. The forecast indicates a 24.50% rise compared to COYA last annual SG&A of $2.38M (Dec 23).

Coya Therapeutics EPS Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Dec 23
# Analysts11123111
EPS-------$0.09
Avg Forecast$-0.45$-0.15$-0.32$-0.36$-0.28$-0.36$-0.17$0.26
High Forecast$-0.45$-0.15$-0.32$-0.36$-0.28$-0.36$-0.17$0.26
Low Forecast$-0.45$-0.15$-0.32$-0.36$-0.28$-0.36$-0.17$0.26
Surprise %-------0.34%

According to 1 Wall Street analysts, Coya Therapeutics's projected average Quarter EPS for Jun 24 is $-0.17, with a low estimate of $-0.17 and a high estimate of $-0.17. This represents a -293.40% decrease compared to COYA previous annual EPS of $0.09 (Dec 23).

Coya Therapeutics Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
INABIN8bio$0.29$14.004727.59%Buy
HLVXHilleVax$1.90$32.001584.21%Hold
STROSutro Biopharma$2.09$13.00522.01%Buy
DRMADermata Therapeutics$1.10$6.00445.45%Buy
INZYInozyme Pharma$2.94$16.00444.22%Buy
OPTOpthea$3.27$14.00328.13%Buy
GANXGain Therapeutics$1.68$7.00316.67%Buy
TCRXTScan Therapeutics$2.97$12.00304.04%Buy
ABOSAcumen Pharmaceuticals$1.96$7.00257.14%Buy
COYACoya Therapeutics$5.61$18.00220.86%Buy
CUECue Biopharma$1.06$3.00183.02%Buy
TERNTerns Pharmaceuticals$6.80$18.67174.56%Buy
FENCFennec Pharmaceuticals$6.07$15.75159.47%Buy
DAWNDay One Biopharmaceuticals$12.64$24.0089.87%Buy
CNTACentessa Pharmaceuticals$17.60$23.2532.10%Buy

COYA Forecast FAQ

Is Coya Therapeutics a good buy?

Yes, according to 3 Wall Street analysts, Coya Therapeutics (COYA) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 3 'Buy' recommendations, accounting for 100.00% of COYA's total ratings.

What is COYA's price target?

Coya Therapeutics (COYA) average price target is $18 with a range of $18 to $18, implying a 243.51% from its last price of $5.24. The data is based on 3 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Coya Therapeutics stock go up soon?

According to Wall Street analysts' prediction for COYA stock, the company can go up by 243.51% (from the last price of $5.24 to the average price target of $18), up by 243.51% based on the highest stock price target, and up by 243.51% based on the lowest stock price target.

Can Coya Therapeutics stock reach $8?

COYA's average twelve months analyst stock price target of $18 supports the claim that Coya Therapeutics can reach $8 in the near future.

What are Coya Therapeutics's analysts' financial forecasts?

Coya Therapeutics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $4.72M (high $4.72M, low $4.72M), average EBITDA is $2.36M (high $2.36M, low $2.36M), average net income is $-12.287M (high $-12.287M, low $-12.287M), average SG&A $5.09M (high $5.09M, low $5.09M), and average EPS is $-0.807 (high $-0.807, low $-0.807). COYA's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $5.38M (high $5.38M, low $5.38M), average EBITDA is $2.69M (high $2.69M, low $2.69M), average net income is $-19.534M (high $-19.534M, low $-19.534M), average SG&A $5.79M (high $5.79M, low $5.79M), and average EPS is $-1.283 (high $-1.283, low $-1.283).

Did the COYA's actual financial results beat the analysts' financial forecasts?

Based on Coya Therapeutics's last annual report (Dec 2023), the company's revenue was $6M, which missed the average analysts forecast of $7.5M by -19.97%. Apple's EBITDA was $-7.903M, missing the average prediction of $3.75M by -310.76%. The company's net income was $-7.988M, missing the average estimation of $3.92M by -303.96%. Apple's SG&A was $7.83M, missing the average forecast of $8.07M by -2.96%. Lastly, the company's EPS was $-0.79, missing the average prediction of $0.257 by -407.03%. In terms of the last quarterly report (Dec 2023), Coya Therapeutics's revenue was $6M, missing the average analysts' forecast of $7.5M by -19.97%. The company's EBITDA was $2.02M, missing the average prediction of $3.75M by -46.26%. Coya Therapeutics's net income was $1.27M, missing the average estimation of $3.92M by -67.68%. The company's SG&A was $2.38M, missing the average forecast of $8.07M by -70.55%. Lastly, the company's EPS was $0.0879, missing the average prediction of $0.257 by -65.84%